Using Nutraceuticals to Help Manage Traumatic Spinal Cord Injury
- PMID: 38256904
- PMCID: PMC10820888
- DOI: 10.3390/ph17010071
Using Nutraceuticals to Help Manage Traumatic Spinal Cord Injury
Abstract
Traumatic spinal cord injury (TSCI) is a significant public health challenge that has an adverse impact on functional independence, quality of life, and life expectancy. Management of people's chronic conditions is a key aspect of contemporary medical practice. Our study was an open label, single arm, prospective pilot study to evaluate the feasibility of treating people with TSCI. The study intervention was treatment with oral selenium and vitamin E. Participants were 18 years or older and experienced a TSCI at least one year prior to enrollment. Daily doses of 50 mcg of selenium and 400 IU of vitamin E were administered. Participants had radiologic (MRI tractography) and clinical (ASIA) assessments prior to initiating treatment, and these assessments were repeated after one year of treatment. Four subjects completed the full twelve-month study. Adherence, based on pill counts, was approximately 75% in all subjects. There were no adverse events related to study medications. During the treatment period, subjects reported improvement in certain symptoms. There was no significant difference in ASIA scores before and after the intervention. Combination treatment with vitamin E and selenium has been demonstrated as safe for TSCI patients. It is possible to use DTI values to locate the epicenter of a lesion as well as gauge the extent of injury. MRI tractography may serve as a meaningful surrogate endpoint. The results of this study suggest that it is feasible to conduct a larger long-term clinical trial to evaluate the efficacy of combination treatment of TSCI.
Keywords: nutraceuticals; selenium; spinal cord injury; tractography; vitamin E.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
Similar articles
-
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217. Cochrane Database Syst Rev. 2022. PMID: 36321557 Free PMC article.
-
Granulocyte-colony stimulating factor administration for neurological improvement in patients with postrehabilitation chronic incomplete traumatic spinal cord injuries: a double-blind randomized controlled clinical trial.J Neurosurg Spine. 2018 Jul;29(1):97-107. doi: 10.3171/2017.11.SPINE17769. Epub 2018 Apr 27. J Neurosurg Spine. 2018. PMID: 29701561 Clinical Trial.
-
Incidence of acute care adverse events and long-term health-related quality of life in patients with TSCI.Spine J. 2015 May 1;15(5):923-32. doi: 10.1016/j.spinee.2013.06.051. Epub 2013 Aug 24. Spine J. 2015. PMID: 23981816
-
Incidence of traumatic spinal cord injury worldwide: A systematic review, data integration, and update.World Neurosurg X. 2023 Feb 1;18:100171. doi: 10.1016/j.wnsx.2023.100171. eCollection 2023 Apr. World Neurosurg X. 2023. PMID: 36910686 Free PMC article. Review.
-
Neurological recovery following traumatic spinal cord injury: a systematic review and meta-analysis.J Neurosurg Spine. 2019 Feb 15;30(5):683-699. doi: 10.3171/2018.10.SPINE18802. Print 2019 May 1. J Neurosurg Spine. 2019. PMID: 30771786 Review.
Cited by
-
Epidemiological Characteristics of Traumatic Spinal Cord Injury in Saudi Arabia: A Systematic Review.Cureus. 2024 Aug 22;16(8):e67531. doi: 10.7759/cureus.67531. eCollection 2024 Aug. Cureus. 2024. PMID: 39310389 Free PMC article. Review.
References
-
- Statistical Center . The 2022 Annual Statistical Report for the Spinal Cord Injury Model Systems. National Spinal Cord Injury Statistical Center; Birmingham, AL, USA: 2022.
-
- National Institutes of Health Selenium Fact Sheet for Professionals. [(accessed on 21 November 2023)]; Available online: https://ods.od.nih.gov/factsheets/Selenium-HealthProfessional/
Grants and funding
LinkOut - more resources
Full Text Sources
